A study using multiplex single cell polymerase chain reaction analyzed the expression of the mediators of the leukotriene pathway in bone marrow BCR-ABL+CD34+CD38− cells at diagnosis found the majority of cells expressed CysLT1R and CysLT2R, but not ALOX5; treatment with zileuton or montelukast failed to suppress cell growth, suggesting that targeting the CysLT pathway may not be a promising strategy to eradicate leukemia stem cells in CML patients [99]. The gene discussed is CYSLTR1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.